According to the lawsuit, the Offering Documents and defendants made false and/or misleading statements and/or failed to disclose that:
- VTX958, Ventyx’s lead clinical product candidate for psoriasis, psoriatic arthritis, and Crohn’s disease, was less effective in treating psoriasis than defendants had led investors to believe;
- as a result, VTX958’s clinical and/or commercial prospects were overstated;
- accordingly, Ventyx had misrepresented its ability to develop and commercialize effective product candidates;
- Ventyx’s post-IPO business prospects were thus inflated; and
- as a result, Ventyx’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.